Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T, Kimura T, Mori K, Suzuki H, Sano T, Otsuka T, Iwamoto Y, Fukuokaya W, Miyajima K, Enei Y, Sakanaka K, Matsukawa A, Onuma H, Obayashi K, Tsuzuki S, Hata K, Shimomura T, Miki J, Egawa S.
Yanagisawa T, et al. Among authors: shimomura t.
Prostate. 2022 Jan;82(1):3-12. doi: 10.1002/pros.24243. Epub 2021 Sep 24.
Prostate. 2022.
PMID: 34559410